This collaboration will capitalise on Absci’s Integrated Drug Creation platform—seamlessly integrating with AstraZeneca’s expertise in oncology, aiming to expedite the discovery of a potentially game-changing cancer therapy.

Under the agreement, Absci will deploy its pioneering generative AI technology to craft a therapeutic candidate antibody tailored for a specific oncology target. The collaboration encompasses an upfront commitment, substantial R&D funding, milestone payments, and royalties on future product sales.

Sean McClain, Founder & CEO of Absci, said: “AstraZeneca is a leader in developing novel treatments in oncology, and we are excited to collaborate with them to design a therapeutic candidate antibody with the potential to improve the lives of cancer patients.”

Absci’s Integrated Drug Creation platform combines generative AI and scalable wet-lab technologies, generating proprietary data by scrutinising millions of protein-protein interactions. This data fuels Absci’s proprietary AI models, facilitating the design of antibodies that are later validated through wet-lab experiments.

This accelerated approach, completing the entire cycle within approximately six weeks, enhances the probability of successful development outcomes for biologic drug candidates.

Puja Sapra, PhD, SVP of Biologics Engineering & Oncology Targeted Delivery at AstraZeneca, commented: “This collaboration is an exciting opportunity to utilise Absci’s de novo AI antibody creation platform to design a potential new antibody therapy in oncology.”

The announcement follows Absci’s recent publication on the design and validation of de novo antibodies using their state-of-the-art ‘zero-shot’ generative AI model.

The collaboration between Absci and AstraZeneca should further help to demonstrate how AI can be used to revolutionise drug discovery.

(Photo by National Cancer Institute on Unsplash)

See also: AI & Big Data Expo: AI’s impact on decision-making in marketing

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London. The comprehensive event is co-located with Cyber Security & Cloud Expo and Digital Transformation Week.

Explore other upcoming enterprise technology events and webinars powered by TechForge here.

The post Absci and AstraZeneca forge AI partnership to discover cancer treatments appeared first on AI News.

LabGenius is currently focused on discovering new treatments for cancer and inflammatory diseases. The firm combines AI, lab automation, and synthetic biology for its potentially life-saving work.

Until now, the company has been using traditional GPUs for its workloads. LabGenius reports that switching to Graphcore’s IPUs in cloud instances from Cirrascale Cloud Services enabled its training of models to be reduced from one month to around two weeks.

“Previously we used GPUs and it took us about a month to have a functioning model of all the proteins that are out there,” said Dr Katya Putintseva, a Machine Learning Advisor to LabGenius.

“With Graphcore, we reduced the turnaround time to about two weeks, so we can experiment much more rapidly and we can see the results quicker.”

Specifically, LabGenius is using IPUs from Bristol, UK-based Graphcore to train a BERT Transformer model on a large data set of known proteins to predict masked amino acids. This, the company says, enables the model to effectively learn the basic biophysics of proteins.

“[The system] is looking across different features we could change about the molecule — from point mutations of simpler constructs to the overall composition and topology of multi-module proteins,” explained Tom Ashworth, Head of Technology at LabGenius.

“It’s making suggestions about what to design next… to learn about a change in the input and how that maps to a change in the output.”

One in two people now develop cancer in their lifetime. Current treatments often cause much suffering themselves and, while survival rates for most forms are increasing, only around 50 percent survive for ten years or more.

AI will help to find new cancer treatments that cause less suffering and greatly increase the odds of long-term survivability. However, while discovering new cancer treatments is the current focus of LabGenius, the company notes how the principles can be applied more widely to find new treatments for other horrible diseases that plague mankind.

“Graphcore has changed what we’re able to do, accelerating our model training time from weeks to days,” adds Ashworth.

“For our data scientists, that’s really transformative. They can move much more at the speed they think.”

(Photo by National Cancer Institute on Unsplash)

Want to learn more about AI and big data from industry leaders? Check out AI & Big Data Expo taking place in Amsterdam, California, and London.

Explore other upcoming enterprise technology events and webinars powered by TechForge here.

The post LabGenius uses Graphcore’s IPUs to speed up drug discovery appeared first on AI News.

Conditions such as Alzheimer’s, Parkinson’s, Huntington’s, and cystic fibrosis are suspected to be caused by misfolded proteins. Being able to predict a protein’s shape enables a greater understanding of its role within the body.

Previous techniques used for determining the shapes of proteins – such as cryo-electron microscopy, nuclear magnetic resonance, and X-ray crystallography – takes years and costs tens of thousands of dollars per structure.

AI, the researchers hope, will enable target shapes to be modelled from scratch without requiring previously solved proteins to be used as templates.

DeepMind calls their AI-powered folding efforts AlphaFold.

AlphaFold uses two different methods to construct predictions of protein structures:

1. 1. The first method repeatedly replaces pieces of a protein structure with new protein fragments, building on a technique commonly used in structural biology. A neural network invents new fragments.

1. The second method is called ‘gradient descent’ which is a mathematical technique applied to entire protein chains rather than pieces and makes small, incremental improvements.

Image Credit: DeepMind

DeepMind says its work is a successful demonstration of how AI can reduce the complexity of tasks such as protein folding; speeding up the diagnosis and treatment of some of the world’s most debilitating conditions.

In a contest organised by the Protein Structure Prediction Centre, AlphaMind was judged the winner among a total 98 algorithms by predicting the shapes of 25 out of 43 proteins. The runner-up, in comparison, could only predict three of the 43 proteins.

“For us, this is a really key moment,” said Demis Hassabis, co-founder and CEO of DeepMind. “This is a lighthouse project, our first major investment in terms of people and resources into a fundamental, very important, real-world scientific problem.”

 Interested in hearing industry leaders discuss subjects like this and their use cases? Attend the co-located AI & Big Data Expo events with upcoming shows in Silicon Valley, London, and Amsterdam to learn more. Co-located with the IoT Tech Expo, Blockchain Expo, and Cyber Security & Cloud Expo.

The post DeepMind is using AI for protein folding breakthroughs appeared first on AI News.

The AI learns from historical patient data to determine what the lowest doses and frequencies of medication delivered the desired results to shrink tumours.

In some cases, the monthly administration of doses was reduced to just twice per year while achieving the same goal. Based on a trial of fifty patients, treatments were reduced to between a quarter and half of the prior doses.

Pratik Shah, Principal Investigator at MIT Media Lab, says:

“We kept the goal, where we have to help patients by reducing tumour sizes but, at the same time, we want to make sure the quality of life — the dosing toxicity — doesn’t lead to overwhelming sickness and harmful side effects.”

Some of the side effects of cancer medication can do more harm than good to a patient’s quality of life. By implementing the AI’s treatment strategy, the least toxic doses can be used.

The current model focuses on glioblastoma treatment.

Glioblastoma is the most aggressive form of brain cancer, although it can also be found in the spinal cord. It’s more commonly found in older adults but can impact any age.

Sufferers are often given a life expectancy of up to five years. Doctors often administer the maximum safe dosages to shrink tumours as much as possible, but with side effects that can impact a patient’s quality of life over that period.

In a press release, MIT said:

“The researchers’ model, at each action, has the flexibility to find a dose that doesn’t necessarily solely maximize tumour reduction, but that strikes a perfect balance between maximum tumour reduction and low toxicity.”

“This technique has various medical and clinical trial applications, where actions for treating patients must be regulated to prevent harmful side effects.”

Reinforced learning was used for the model whereby the AI seeks ‘rewards’ and wants to avoid ‘penalties’ so it optimises all of its actions.

The model started by determining whether to administer or withhold a dose. If administered, whether a full dose or just a portion is necessary.

A second clinical model is pinged each time an action is taken in order to predict the effect on the tumour.

In order to prevent just giving frequent maximum dosages each time – the researchers’ AI received a penalty whenever it handed out full doses, or a medication too often.

Without the penalty in place, the results were very similar to a treatment regime created by humans. With the penalties, the frequency and potency of the doses were significantly reduced.

The full research paper can be found here (PDF)

What are your thoughts on using AI to improve cancer patients’ quality of life? Let us know in the comments.

 Interested in hearing industry leaders discuss subjects like this and sharing their use-cases? Attend the co-located AI & Big Data Expo events with upcoming shows in Silicon Valley, London and Amsterdam to learn more. Co-located with the  IoT Tech Expo, Blockchain Expo and Cyber Security & Cloud Expo so you can explore the future of enterprise technology in one place.

The post AI is helping to make treatment for cancer more bearable appeared first on AI News.

How long it takes for radiation therapy plans to be created today can take days. Individual maps need to be created for each patient to determine where tumours need to be targeted.

This lengthy process is frustrating for the patient, their loved ones, and medical professionals who’d love nothing more than to spend time saving lives instead of creating plans.

Engineering researcher Aaron Babier and his team have stepped-in with AI-based software to automate the process and cut down how long it takes for a radiation therapy plan to be created from days to hours, potentially even minutes.

The team – from the University of Toronto’s Department of Mechanical & Industrial Engineering – also includes Justin Boutilier, Professor Timothy Chan, and Professor Andrea McNiven. Each of the researchers sees radiation therapy design as an optimisation problem.

By analysing historical radiation therapy data, the AI behind the software applied it to an optimisation engine to develop treatment plans. When the plans their software tool created was compared with those manually created for 217 patients treated for throat cancer, they were almost indistinguishable.

The difference, however, is their AI-powered tool created the plans within 20 minutes.

Babier explained:

“Right now treatment planners have this big time sink. If we can intelligently burn this time sink, they’ll be able to focus on other aspects of treatment.

The idea of having automation and streamlining jobs will help make health-care costs more efficient. I think it’ll really help to ensure high-quality care.”

Most of us have some unwelcome connection to cancer. According to statistics, one in two people in the UK born after 1960 will be diagnosed with some form of cancer during their lifetime.

Babier has a personal vendetta against the disease. He shares when he was 12 years old his stepmom sadly passed away from a brain tumour.

“I think it’s something that’s always been at the back of my head. I know what I want to do, and that’s to improve cancer treatment,” he says. “I have a family connection to it.”

What are your thoughts on the use of AI in cancer treatment? Let us know in the comments.

 Interested in hearing industry leaders discuss subjects like this and sharing their use-cases? Attend the co-located AI & Big Data Expo events with upcoming shows in Silicon Valley, London and Amsterdam to learn more. Co-located with the  IoT Tech Expo, Blockchain Expo and Cyber Security & Cloud Expo so you can explore the future of enterprise technology in one place.

The post AI slashes cancer treatment plan creation to ‘mere hours’ appeared first on AI News.